During the current project period, CCSG Developmental Funds were efficiently and productively used to fund innovative Pilot cancer research projects and provide critical support to developing Shared Resources. In the current application, YCC proposes focusing the allotted Developmental Funds entirely on the Pilot Project Program, a highly successful intramural grants program to stimulate innovative, early stage cancer research. In addition to the Pilot Projects, in which individual investigators receive funding for research projects, YCC members can also compete for funding of larger multi-Investigator projects for collaborative, transdisciplinary work. In a new program, YCC members collaborating with cancer investigators from University College London are also eligible for collaborative multi-institutional project awards, which create closer research interactions between the two Institutions. In recognition of the strategic imperative of strengthening translational research, Translational Targeted Areas of Research Excellence (T-TARE) Awards were initiated in 2011 to support translational research in cancer, requiring a collaborative effort among 3 or more YCC members. These research projects match clinical and basic scientists in ongoing productive collaborations and are designed to evolve into successful translational applications and new clinical trials. Pilot awards are intended to facilitate and expedite the maturation of individual as well as collaborative projects into external peer-reviewed funding, anchored in the YCC.
Developmental Funds from the CCSG have been used effectively by YCC investigators to expand cancer research in alignment with center-wide and programmatic priorities. The Pilot Project Program supports new research projects that are innovative, collaborative, transdisciplinary, and translational in approach and is likely to result in additional external peer-reviewed funding.
|Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326|
|Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083|
|Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291|
|Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40|
|Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631|
|Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025|
|Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461|
|Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853|
|Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573|
|Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331|
Showing the most recent 10 out of 675 publications